The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel.

The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel.

Bisphosphonates are well established in the management of breast-cancer-induced bone disease. Recent studies have suggested that these compounds are effective in preventing the development of bone metastases. However, it is unclear whether this reflects an indirect effect via an inhibition of bone r...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Jagdev, S, Coleman, R, Shipman, C, Rostami-H, A, Croucher, P
Natura:	Journal article
Lingua:	English
Pubblicazione:	2001

Documenti analoghi

Bones, breasts, and bisphosphonates: rationale for the use of zoledronic acid in advanced and early breast cancer
di: Allan Lipton
Pubblicazione: (2011-03-01)

Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity.
di: Shipman, C, et al.
Pubblicazione: (1997)

Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management
di: Luca Dalle Carbonare, et al.
Pubblicazione: (2010-08-01)

Geranylgeraniol Restores Zoledronic Acid-Induced Efferocytosis Inhibition in Bisphosphonate-Related Osteonecrosis of the Jaw
di: Xin Chen, et al.
Pubblicazione: (2021-11-01)

Bisphosphonates and in vivo models of multiple myeloma - Reply
di: Shipman, C, et al.
Pubblicazione: (2001)

The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway.
di: Shipman, C, et al.
Pubblicazione: (1998)

Safety of Intravitreal Zoledronic Acid, an Anti-angiogenic Bisphosphonate, in a Rat Model
di: Ramin Nourinia, et al.
Pubblicazione: (2014-01-01)

The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.
di: Shipman, C, et al.
Pubblicazione: (2000)

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
di: Croucher, P, et al.
Pubblicazione: (2003)

The bisphosphonates alendronate and zoledronate induce adaptations of aerobic metabolism in permanent human endothelial cells
di: Adrianna Budzinska, et al.
Pubblicazione: (2023-09-01)

Letrozole and zoledronic acid changed signalling pathways involved in the apoptosis of breast cancer cells
di: Salah A. Sheweita, PhD, et al.
Pubblicazione: (2021-02-01)

Nitrogen-containing bisphosphonates induce apoptosis in human bone marrow-derived myeloma cells in vitro by inhibiting protein prenylation.
di: Gordon, S, et al.
Pubblicazione: (1999)

Activation of BK(Ca) channels in zoledronic acid-induced apoptosis of MDA-MB-231 breast cancer cells.
di: Yu-Guang Ma, et al.
Pubblicazione: (2012-01-01)

Zoledronic acid prevents the development of myeloma bone disease and increases survival
di: Shipman, C, et al.
Pubblicazione: (2002)

Bone targeting compounds for radiotherapy and imaging: *Me(III)-DOTA conjugates of bisphosphonic acid, pamidronic acid and zoledronic acid
di: M. Meckel, et al.
Pubblicazione: (2016-09-01)

Bisphosphonates--mechanisms of action in multiple myeloma.
di: Shipman, C, et al.
Pubblicazione: (2000)

Anti-tumour activity of bisphosphonates in human myeloma cells.
di: Shipman, C, et al.
Pubblicazione: (1998)

Zoledronic acid in breast cancer: latest findings and interpretations
di: Michael Gnant
Pubblicazione: (2011-11-01)

Zoledronic acid inhibits the development of osteolytic bone disease and increases disease free survival in a murine model of multiple myeloma.
di: Croucher, P, et al.
Pubblicazione: (2001)

Zoledronic Acid-Induced Insulitis in Rats
di: Heresh Rezaei, et al.
Pubblicazione: (2023-06-01)

The pharmacology of bisphosphonates and new insights into their mechanisms of action.
di: Russell, R, et al.
Pubblicazione: (1999)

Zoledronic acid prevents the development of osteolytic bone disease and increases survival in a murine model of multiple myeloma
di: Croucher, P, et al.
Pubblicazione: (2002)

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.
di: Croucher, P, et al.
Pubblicazione: (2003)

Zoledronic acid induced unilateral anterior uveitis
di: Shipra Gupta, et al.
Pubblicazione: (2020-01-01)

Osteoprotegerin (OPG) is a soluble decoy receptor for TRAIL/Apo2L and can inhibit TRAIL/Apo2L-induced apoptosis of human myeloma cells in vitro.
di: Shipman, C, et al.
Pubblicazione: (2002)

Boosting synergism of chemo- and immuno-therapies via switching paclitaxel-induced apoptosis to mevalonate metabolism-triggered ferroptosis by bisphosphonate coordination lipid nanogranules
di: Ge Song, et al.
Pubblicazione: (2024-02-01)

Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
di: Shipman, C, et al.
Pubblicazione: (2003)

Dosing of zoledronic acid with its anti-tumor effects in breast cancer
di: Xinmin Zhao, et al.
Pubblicazione: (2015-09-01)

Unilateral anterior uveitis complicating zoledronic acid therapy in breast cancer
di: El Saghir Nagi S, et al.
Pubblicazione: (2005-12-01)

Comparison of a Novel Bisphosphonate Prodrug and Zoledronic Acid in the Induction of Cytotoxicity in Human Vγ2Vδ2 T Cells
di: Daisuke Okuno, et al.
Pubblicazione: (2020-07-01)

Paclitaxel-induced apoptosis is BAK-dependent, but BAX and BIM-independent in breast tumor.
di: Anna V Miller, et al.
Pubblicazione: (2013-01-01)

Spectrum of activity and mechanisms of azole–bisphosphonate synergy in pathogenic Candida
di: Aidan Kane, et al.
Pubblicazione: (2024-06-01)

Zoledronic acid blocks the interaction between breast cancer cells and regulatory T-cells
di: Hsien Liu, et al.
Pubblicazione: (2019-02-01)

The bisphosphonate zoledronate prevents vertebral bone loss in mature estrogen-deficient rats as assessed by micro-computed tomography
di: Glatt M.
Pubblicazione: (2001-01-01)

Synergy of Nab-paclitaxel and Bevacizumab in Eradicating Large Orthotopic Breast Tumors and Preexisting Metastases
di: Lisa D. Volk, et al.
Pubblicazione: (2011-04-01)

Cells of the bone marrow microenvironment protect myeloma cells from apoptosis induced by TRAIL but not by agonists of TRAIL death receptors.
di: Locklin, R, et al.
Pubblicazione: (2005)

Combined Use of Zoledronic Acid Augments Ursolic Acid-Induced Apoptosis in Human Osteosarcoma Cells through Enhanced Oxidative Stress and Autophagy
di: Chia-Chieh Wu, et al.
Pubblicazione: (2016-11-01)

Drug-Induced Autoimmune Hepatitis following Treatment with Zoledronic Acid
di: Jenny Sarah Schneider, et al.
Pubblicazione: (2017-08-01)

Efficacy and safety of zoledronic acid in the treatment of glucocorticoid-induced osteoporosis
di: Ege Can Serefoglu, et al.
Pubblicazione: (2010-05-01)

Inhibition of breast cancer cell proliferation in repeated and non-repeated treatment with zoledronic acid
di: Ibrahim Toni, et al.
Pubblicazione: (2012-11-01)